Levetiracetam Arrow Lab (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This reduces neuronal hyper‑excitability and stabilises synaptic transmission, thereby decreasing the likelihood of epileptic discharges without directly affecting ion channels or GABA receptors.

The specific dose of Levetiracetam Arrow Lab is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals set the appropriate regimen and adjust it as needed.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and discuss options with the patient. Breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable interaction profile compared with many enzyme‑inducing antiepileptics. It is often preferred when clinicians seek a drug with minimal hepatic metabolism and fewer drug‑drug interactions, though individual response varies.

Levetiracetam Arrow Lab should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. If temperature excursions occur, discard the product according to local regulations.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel, typically as a slow infusion over several minutes, following the dosing instructions provided by the prescriber.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, psychiatric events like depression or suicidal thoughts, and rare hematologic abnormalities such as thrombocytopenia. Patients should be monitored closely for any of these signs.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised in patients with severe renal impairment, uncontrolled psychiatric disorders, or those taking medications that may precipitate serious skin reactions.